Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects
NCT ID: NCT02708004
Last Updated: 2022-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2016-06-01
2016-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention
NCT07318103
To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women
NCT04281342
Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure
NCT03440970
A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
NCT00234104
0.5M Na Lactate Solution in Acute Heart Failure (AHF)
NCT01981655
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACT-132577
3 different dose levels
Aprocitentan
Formulated in capsules in 2 different strengths; 2 capsules per day
Placebo
Matching active drug
Placebo
Matching active drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aprocitentan
Formulated in capsules in 2 different strengths; 2 capsules per day
Placebo
Matching active drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy on the basis of medical history, physical examination, cardiovascular assessments and hematology, clinical chemistry, and urinalysis tests
* Body mass index between 20.0 and 25.0 kg/m2 (inclusive) at screening
Exclusion Criteria
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Idorsia Pharmaceuticals Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trial
Role: STUDY_DIRECTOR
Idorsia Pharmaceuticals Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigator Site Lausanne
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AC-080-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.